Sagittarius Bio

Sagittarius Bio is a private, pre-clinical stage biotech startup targeting high-need areas in immunology, inflammation, and oncology with an undisclosed RNA/gene therapy platform. With a planned launch in Q1 2026, the company is likely in a foundational R&D and platform validation phase, operating with a small team typical of an early-stage venture. Its success will hinge on the novelty and efficacy of its underlying technology, which remains to be publicly detailed, and its ability to secure significant venture funding to advance programs toward the clinic.

Undisclosed RNA and gene therapy platform targeting immunological, inflammatory pathways and oncology.

Sagittarius Bio operates in the highly competitive RNA and gene therapy space, competing against well-funded public companies (e.g., Moderna, BioNTech, Alnylam, Intellia) and numerous private startups, all targeting similar immunological and oncology indications with advanced genetic medicines.